FLT4-targeted drugs famitinib, catequentinib, sunitinib, and axitinib are undergoing phase I/II trials for various cancers, including nasopharyngeal carcinoma, renal cell carcinoma, colorectal adenocarcinoma, lung cancer, and prostate cancer. This evidence concerns the gene FLT4 and renal cell carcinoma.